1	Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients
2	
3	Natalia Ruetalo ¹ , Ramona Businger ¹ , Karina Althaus ² , Simon Fink ³ , Felix Ruoff ³
4	Klaus Hamprecht ¹ , Bertram Flehmig ⁴ , Tamam Bakchoul ² , Markus F. Templin ³ ,
5	Michael Schindler ^{1*}
6	
7	¹ Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital
8	Tübingen, Tübingen, Germany
9	² Institute for Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
10	³ NMI, Reutlingen, Germany
11	⁴ Mediagnost GmbH, Reutlingen, Germany
12	
13	
14	
15	
16	
17	
18	
19	*Correspondence should be addressed to:
20	Michael Schindler, michael.schindler@med.uni-tuebingen.de
21	
22	
23	
24	

25 Abstract

The majority of infections with SARS-CoV-2 (SCoV2) are asymptomatic or mild without the necessity of hospitalization. It is of outmost importance to reveal if these patients develop an antibody response against SCoV2 and to define which antibodies confer virus neutralization. We hence conducted a comprehensive serological survey of 49 patients with a mild course of disease and quantified neutralizing antibody responses against authentic SCoV2 employing human cells as targets.

32 Four patients (8%), even though symptomatic, did not develop antibodies against SCoV2 33 and two other sera (4%) were only positive in one of the serological assays employed. 34 For the remainder, antibody response against the S-protein correlated with serum 35 neutralization whereas antibodies against the nucleocapsid were poor predictors of virus 36 neutralization. Only six sera (12%) could be classified as highly neutralizing. 37 Furthermore, sera from several individuals with fairly high antibody levels had only poor 38 neutralizing activity. In addition, our data suggest that antibodies against the seasonal 39 coronavirus 229E contribute to SCoV2 neutralization.

Altogether, we show that there is a wide breadth of antibody responses against SCoV2 in patients that differentially correlate with virus neutralization. This highlights the difficulty to define reliable surrogate markers for immunity against SCoV2.

- 43
- 44
- 45

46

47

48

49 Introduction

50 The most recent emerging virus outbreak happened in China in December 2019 caused 51 by SARS (severe acute respiratory syndrome) coronavirus-2 (SCoV2) (1), leading to a 52 pandemic, as defined by the WHO in March 2020 (2, 3). Infections with SCoV2 can 53 cause the so-called disease COVID-19 (Coronavirus disease 2019). 50% of all COVID-54 19 cases range from asymptomatic to mild. 30% show moderate to pronounced 55 symptoms. 5-20% of patients are hospitalized due to critical course of infection with 56 severe lung complications and on average ~5% die, even though there is high variation dependent on the country (4). Recent data from a multicentric cohort of 10021 57 58 hospitalized COVID-19 patients, showed an in-hospital mortality of 73% in mechanically 59 ventilated patients requiring dialysis, and of 53% of invasively ventilated patients (5). 60 One critical determinant of illness is age, as mortality is highest in the elderly population 61 (1, 2, 4, 5). SCoV2 is currently spreading in an immune naive population and a vaccine is 62 not yet available, even though there are numerous candidates in the advanced 63 For online development pipeline (6). an updated resource refer to 64 https://biorender.com/covid-vaccine-tracker.

The pandemic is not only devastating in terms of the direct harm to human health inflicted by the virus infection, but the continuous quarantine and lock-down measurements have enormous negative impact on the socio-economical life of billions of individuals (7). With the potential of achieving herd immunity as the virus spreads within the population, numerous studies analyzing the prevalence of SCoV2-specific antibodies in the population have been initiated (8-11).

Regardless of the prevalence of antibodies against SCoV2, one critical and still poorly
defined determinant is the ability of antibodies to neutralize SCoV2 and hence potentially

confer protective immunity against the infection. Besides, antibodies that bind to SCoV2 but do not result in neutralization might enhance infection, a phenomenon called antibody-dependent enhancement (12), which has not been investigated either. Finally, the role of cross-protecting antibodies from seasonal coronaviruses is also discussed, but not yet experimentally assessed (12). To shed light on the determinants of human serum to neutralize SCoV2 we performed a comprehensive serological analysis of 49 individuals that were non-hospitalized and range from an asymptomatic to a mild course of disease. We employed several assays measuring SCoV2-specific IgGs against the S-protein, the S-protein RBD, and the nucleocapsid. Furthermore, we assessed S-RBD specific IgM and IgA and used a novel innovative throughput Western-blot system to detect IgGs against SCoV2 and seasonal

84 coronaviruses. Finally, all serological parameters were associated with the ability of the

49 sera to neutralize the infection on human cells with a clinical SCoV2 isolate.

97 Results

98 The majority of patients develop SCoV2-specific antibodies

99 For our serological survey, we recruited individuals coming to the Department of 100 Transfusion Medicine to donate blood for plasma therapy. All 49 patients included in this 101 study were non-hospitalized with asymptomatic to mild courses of disease, including 102 cough (69%), fever (59%), limb pain and headache (35%), diarrhea (10%), and loss of 103 taste (10%) (Supplementary Table 1). The age ranged from 19-66 years (median 40 104 years), gender was balanced (24 male, 25 female). The time from positive SARS-CoV-2 105 test to blood sampling was 14-64 days (median 45 days).

We employed several serological assays to detect antibodies against SCoV2 (Table 1 and Supplementary Table 1). IgG ELISAs against the S-protein (Euroimmune) and Sprotein RBD (Mediagnost), IgA and IgM against S-RBD (Mediagnost) as well as an ECLIA detecting IgG against the viral nucleocapsid (NC, Roche). Furthermore, we applied a throughput Western blot system (DigiWest) allowing detection of SCoV2 and seasonal coronavirus antibodies (13).

4/49 (8%) sera were negative in all serological assays employed to detect SCoV2specific antibodies, even though they were symptomatic showing two or more symptoms. In addition, two more sera were only positive in one of the four assay systems to detect IgGs against S or NC. Apart from the robust IgG-response both against the S-protein (90%) and NC (80%), development of S-specific IgM and IgA was less prominent, with 35 and 30% of positive sera respectively (Supplementary Table 1).

In sum, even though 12% (6/49) of patients did not develop antibodies against SCoV2,
the vast majority (88%, 43/49) of individuals mount a robust SCoV2-specific antibody
response.

121 Few patients develop high virus neutralizing titers (VNTs) after SCoV2 infection

122 The majority of SARS-CoV-2 infected individuals seroconvert within 14 days (Guo et al... 123 2020); however, it is unclear if sera from these patients neutralize SCoV2. To test for 124 virus neutralization we established two procedures using human Caco-2 cells as targets 125 (Fig. 1a). First, we infected cells with a SCoV2 strain isolated from a throat swab of a 126 patient showing a high viral load as determined by gRT-PCR. This strain was designated 127 SCoV2 200325 Tü1. Cells were co-incubated with patient sera and virus in serial two-128 fold dilutions from 1:20 up to 1:2560. 48 hpi cells were fixed with 80% acetone and 129 immunofluorescence stained against SCov2 antigens with a highly potent patient serum 130 we retrieved from a hospitalized convalescent donor. Cells were counter-stained with 131 DAPI and infection rates quantified via automated fluorescence-microscopy. For the 132 second approach, we employed the mNeonGreen expressing infectious SCoV2 clone 133 [12]. Cells were treated and infected exactly as explained for the SCoV2 Tü1 strain, but 134 using slightly adjusted dilutions of sera; 1:40 to 1:5120. 48 hpi cells were fixed with 2% 135 PFA containing Hoechst33342 as nuclear stain (Fig. 1b, representative sera examples of 136 both procedures). Infection rates of the corresponding serum dilutions were used to plot 137 sigmoidal inhibition curves and calculate the virus-neutralizing titer 50 (VNT₅₀) which is 138 the serum dilution inhibiting the half-maximal infection (Fig. 1c). The VNT₅₀ values of the 139 sera obtained with the primary patient isolate correlated highly significantly with the titers 140 calculated when using the mNeonGreen-expressing infectious clone (r=0.7349; Fig.1d). 141 We only obtained slight discrepancies for highly potent sera that seemed to neutralize 142 SCoV2-mNG more efficiently than SCoV2-Tü1 at high dilutions. In both assays, sera 143 from four healthy donors and two consecutive sera from a hospitalized convalescent 144 patient were either completely negative for VNT as well as all serological assays, or

145 showed robust neutralization and SCoV2-specific antibodies (Table 1).

Patient sera were classified according to their neutralizing capacity (Fig. 1e) revealing that only 12% (6/49) were highly potent neutralizers. 8% (4/49) of sera did not neutralize SCoV2 at all *in vitro* and 24% (12/49) were poor neutralizers even though showing robust signals in the different serological assays employed. Hence, there is a large diversity in the ability of patient sera to neutralize SCoV2 which is not always associated with the amount of SCoV2-specific antibodies.

152

153 VNT₅₀ is not associated with specific patient characteristics, apart from gender

154 We next assessed potential associations of patient characteristics with serum 155 neutralization. Neither the sampling date 14-64 days (Fig. 2a) nor patient age (Fig. 2b) 156 correlated with serum neutralization. This indicates that seroconversion, as reported, is achieved within 14 days in all patients and VNTs might not drop up to 64 days. On 157 158 average, titers were higher in males as compared to females (Fig. 2c). In detail, 3/4 159 individuals that did not neutralize at all were female but 5/6 highly potent neutralizers 160 were male (Supplementary Table 1). Furthermore, the average VNT_{50} of men is double 161 as compared to women (613 vs 322; compare Fig. 2c). Of note, there was no association 162 of VNT_{50} with the severity of disease (Fig. 2d), respectively amount of symptoms.

163

164 SCoV2-specific IgG against the S-protein RBD indicate serum neutralization

165 Next, we set out to define serological correlates of virus neutralization *in vitro*. Overall, 166 the neutralizing capacity of the sera correlated with the abundance of SCoV2 specific 167 IgG against the S-protein (r=0.6137; Fig. 3a), with a slightly better r-value when the IgG-168 measured were RBD-specific (r=0.7198; Fig. 3b). This indicates, as expected, that

antibodies against the RBD are critically involved in SCoV2-neutralization. Similarly,
RBD-specific IgA and IgM seem to contribute to neutralization (Fig. 3c and Fig. 3d), even
though their abundance is highly diverse in the patient cohort (Supplementary Table 1).
In contrast, IgGs against the SCoV2-nucleocapsid measured by the Roche ECLIA were
only poor predictors of serum neutralization (r=0.3249; Fig. 3d).

174 In conclusion, ELISAs or antibody tests, quantifying antibodies against the S-protein and

175 in particular the S-RBD seem to correlate best with patient serum neutralization.

176

Antibodies against seasonal coronavirus 229E contribute to serum neutralization of SCoV2

179 It is a matter of ongoing debate if antibodies against seasonal coronaviruses might 180 confer cross-protection against SARS-CoV-2. To get first insights into this question, we 181 took use of a quantitative throughput Western blot-based detection system identifying the 182 bulk of IgGs against a specific coronavirus (13). As expected and in line with our 183 previous data (Fig. 3a and 3b), IgG against SCoV2 correlated with VNT₅₀ (r=0.6592; Fig. 184 4a). Of note, IgG against the seasonal coronavirus 229E was also associated with VNT_{50} 185 (r=0.4136, p=0.0017; Fig. 4b), indicating that this class of antibodies might support 186 SCoV2 neutralization. Remarkably, this effect was specific for 229E and neither 187 observed for seasonal coronaviruses OC43 (Fig. 4c) nor NL63 (Fig. 4d). In conclusion, 188 even though effects might be minor as compared to the antibodies mounted against 189 SCoV2-S-RBD, a humoral immune response against the seasonal coronavirus 229E 190 might support SCoV2 neutralization.

191

193 Discussion

194 Recent studies assessed the development of virus-specific antibodies in various cohorts 195 of COVID-19 convalescent individuals (14-16). Overall, the data of the latter is in 196 accordance with ours, showing that the vast majority of individuals develop SCoV2-197 specific antibodies. Furthermore, SCoV2-specific IgGs were more prevalent than IgMs 198 (15, 16), a finding that we confirm and extend to the abundance of SCoV2-specific IqA. 199 Using pseudovirus-based neutralization assays Robbiani et al. (15) also report that there 200 is a correlation between VNT₅₀ and antibodies against the S-RBD. Furthermore, males 201 had significantly higher neutralizing activity than females, a finding which is also 202 supported by our data (Fig. 2c). We critically extend the aforementioned studies by 203 several highly relevant aspects. First, for all our neutralization experiments we employed 204 an authentic fully infectious clinical SCoV2-isolate on a human cell line, an approach that 205 was not used before to determine correlates of SCoV2 serum neutralization. Second, we 206 performed a comprehensive comparison of several serological tests to delineate 207 correlates of SCoV2 neutralization. This revealed that NC-specific antibodies are poor 208 predictors of serum virus neutralization. In contrast, as supported by the findings of 209 Robbiani et al. (17) and Ju et al (18) RBD-specific IgGs seem to correlate best with 210 serum neutralization (Fig. 3b). In this context, it is remarkable that S-RBD specific IgA 211 and IgM also showed a high degree of correlation with the VNT₅₀ (Fig. 3c and 3d), 212 indicating that these antibodies, even though their abundance was highly diverse in our 213 patient cohort, contributes to serum neutralization.

A phenomenon that is critically discussed is the potential enhancement of infection by non-neutralizing antibodies (ADE) (12). For our VNT-assays, we are using human cells expressing a diverse set of F_c -receptors, and directly assess the rate of infected cells by

217 immunofluorescence or reporter-gene expression. Hence, we should be able to detect 218 enhancement of infection by serum that is not or only poorly neutralizing and in higher 219 dilution ranges. However, in none of our 49 sera we observed ADE at any of the dilutions 220 tested, indicating that at least antibodies generated in the natural context of SCoV2 221 infection do not contribute to severity of infection. This is in line with the absence of a 222 correlation between the number of symptoms and VNT_{50} in our patients (Fig. 2d). On the 223 other hand, our cohort is biased due to the fact that none of the patients was 224 hospitalized. Therefore, it will be important to analyze if ADE plays a potential role in 225 severe cases of COVID-19.

226 Up to now, it was elusive if antibodies against seasonal coronaviruses that are highly 227 prevalent within the human population play a role in SCoV2 neutralization. We employed 228 an innovative throughput Western blot system to concomitantly detect antibodies specific 229 against SCoV2 as well as the seasonal coronaviruses 229E. OC43 and NL63 (13). In 230 fact, 100% of individuals included in our study had antibodies against the three seasonal 231 coronaviruses with high diversity in relative numbers (Supplementary Table 1). 232 Correlating the latter with our VNT₅₀ values revealed a significant association of 229E-233 specific IgGs with the ability of patient sera to neutralize SCoV2 infection (Fig. 4b). 234 Remarkably, this effect was 229E-specific since none of the other seasonal 235 coronaviruses showed such an association (Fig. 4c and 4d). While it is clear that 229Especific IgGs are not sufficient to confer cross-protection against SCoV2, our data imply 236 237 that the prevalence of such antibodies assists in the neutralization of SCoV2. A 238 hypothesis that is in line with the observation that antibodies directed against the RBD of 239 SARS or MERS alone are not sufficient to inactive SCoV2 (18). It will be highly 240 interesting to analyze if the epidemiology of seasonal coronaviruses is a determinant of

241 COVID-19 severity, with the implication that in areas with a high prevalence of antibodies242 against 229E mortality is decreased.

243 Altogether, we here establish several correlates of SCoV2 neutralization by patient 244 serum using a relevant virus-neutralization test. Even though S-RBD-specific IgGs 245 correlate best with serum neutralization, it is clear that multiple factors contribute to a 246 potent neutralizing antibody response. This might include subclasses of S-specific 247 antibodies as for instance IgM and IgA as well as the antibody response elicited against 248 the seasonal coronavirus 229E. This makes it particularly difficult to define singular 249 serological correlates of immune protection as discussed in the context of COVID-19 250 "immunity passports". Furthermore, such an approach neglects other potentially essential 251 factors of immune protection as for instance, T-cell mediated immunity (19, 20) and the 252 innate immune response (21).

253

254 Author contributions

255 NR, RB, and MS established the neutralization test and performed all experiments with 256 SCoV2; KA and TB provided patient samples and did the Euroimmune ELISA; BF 257 performed all ELISAs provided by Mediagnost; KH established, analyzed and supervised 258 the Roche ECLIA; SF, FR and MT established, conducted and analyzed the DigiWest 259 detection system for SCoV2 and seasonal CoVs; NR, RB, and MS analyzed the data; 260 NR and MS drafted the figures and wrote the manuscript. MS developed the manuscript 261 to its final form; MS planned and supervised the study; all authors read, edited, and 262 approved the final manuscript.

263

264

265 **Conflict of interest**

- 266 The authors report no conflict of interest
- 267

268 Acknowledgements

- 269 We thank all patients and healthy volunteer donors for their cooperation in this study and
- 270 for their swab specimen collection and blood donation. We thank Thomas Iftner and Tina
- 271 Ganzenmüller for their support with diagnostic tests and the collection of swab 272 specimens.
- 273

274 Funding

275 This work was supported by grants to MS from the Baden-Württemberg foundation (BW-

276 Stiftung), the Deutsche Forschungsgemeinschaft as well as by basic funding provided to

277 MS by the University Hospital Tübingen and TÜFF-Gleichstellungsförderung to K.A.

- 278 (2563-0-0).
- 279
- 280
- 281
- 282
- 283
- 284
- 285
- 286

287

201

289 **References**

290 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from 291 Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

292 2. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. 293 Virological assessment of hospitalized patients with COVID-2019. Nature. 294 2020;581(7809):465-9.

295 3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global 296 health concern. Lancet. 2020;395(10223):470-3.

4. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946.

301 5. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G,
302 et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID303 19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020.

304 6. Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics, therapy 305 and vaccination. Theranostics. 2020;10(17):7821-35.

Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socioeconomic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg.
2020;78:185-93.

8. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda
M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, populationbased seroepidemiological study. Lancet. 2020.

9. Vodicar PM, Valencak AO, Zupan B, Zupanc TA, Kurdija S, Korva M, et al. Low
prevalence of active COVID-19 in Slovenia: a nationwide population study on a
probability-based sample. Clin Microbiol Infect. 2020.

315 10. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower
316 prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
317 Antiviral Res. 2020:104880.

318 11. Oude Munnink BB, Nieuwenhuijse DF, Stein M, O'Toole A, Haverkate M, Mollers
319 M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public
320 health decision-making in the Netherlands. Nat Med. 2020.

321 12. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et
322 al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
323 Nature. 2020.

324 13. Simon F, Ruoff F, Stahl A, Becker M, Kaiser P, Traenkle B, et al. A throughput
 325 serological Western blot system using whole virus lysate for the concomitant detection of
 326 antibodies against SARS-CoV-2 and human endemic Coronaviridae. medRxiv. 2020.


327 14. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV328 2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
329 Immunity. 2020;52(6):971-7 e3.

15. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature.
2020.

16. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and
immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020.

- 335 17. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An 336 Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe. 2020;27(5):841-8 e3.
- 18. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020.
- Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected
 controls. Nature. 2020.
- 342 20. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-343 reactive T cells in healthy donors and patients with COVID-19. Nature. 2020.
- 344 21. McKechnie JL, Blish CA. The Innate Immune System: Fighting on the Front Lines 345 or Fanning the Flames of COVID-19? Cell Host Microbe. 2020;27(6):863-9.

- 364 Figures and Table



366 Figure 1. Neutralization of SCoV2 by sera of COVID-19 convalescent patients. (a)

367 Experimental layout of the two neutralization assays employed using the clinical isolate 368 (SCoV2 Tü1) and the green-fluorescent virus (SCoV2 mNG). (b) Primary data showing 369 results of both neutralization assays using one patient serum as an example (S28). In 370 the upper row, the total amount of cells for each well of the two-fold serial dilution of sera 371 is shown, as DAPI+/Hoechst+ respectively. In the lower, infected cells are visualized, 372 indicated as Alexa594+/mNG+ cells, respectively. (c) Neutralization curves of five 373 representative sera measured by both assays. The graphs show the nonlinear 374 regression fitting calculated for five patients who displayed different neutralization 375 capacity: no, poor, low, medium, and high neutralization. The VNT_{50} for each patient are 376 shown next to each curve. (d) Correlation analysis of VNT_{50} measured by both assays 377 (n=49). (d) Percentage of patients classified according to the VNT₅₀ using SCoV2 Tü1. 378 The titers used to classify the sera are shown below the columns: <20, 20-200, 201-400, 379 401-1000 and 1000-2560. Above the columns is shown the percentage of sera that 380 correspond to each category.

381

382

383


384

385

386

387

388






391


Figure 2. Association of patient characteristics with sera VNT₅₀. The VNT₅₀ of each patient serum was associated with the individual (a) date of the positive SCoV2 qRT-PCR diagnostic test to blood sampling, (b) the age of the patient, (c) the gender and (d) the number of symptoms reported. Statistical analyses were done with an unpaired twotailed student's t-test. See detailed patient characteristic in Supplementary Table 1.

- 398
- 399
- 400
- 401
- 402



403

404 Figure 3. Correlation of serological parameters with sera VNT₅₀. The VNT₅₀ of each 405 patient serum was correlated with (a) the value of SCoV2-S-specific IgGs measured by the Euroimmune ELISA, (b) the relative quantitative value of SCoV2-S-RBD-specific 406 407 IgGs measured by the Mediagnost ELISA, (c) the relative guantitative value of SCoV2-S-408 RBD-specific IgAs measured by the Mediagnost ELISA, (d) the relative guantitative value 409 of SCoV2-S-RBD-specific IgMs measured by the Mediagnost ELISA (e) the relative 410 quantitative value of SCoV2-NC-specific IgGs measured by the Roche ECLIA. Dotted 411 lines indicate the respective assay thresholds defined as positive.



413

Figure 4. Correlation of antibodies against seasonal coronaviruses with sera VNT₅₀. The VNT₅₀ of each patient serum was correlated with the relative quantitative value of a throughput diagnostic Western blot detection system measuring CoV-specific IgG against (a) SCoV2, (b) CoV-229E, (c) CoV-OC43 or (d) CoV-NL64. Dotted lines indicate the respective assay thresholds defined as positive.

- 420
- 421
- 422
- 423
- 424

Patient ID	IgG S	IgG S-RBD		SCoV-2 IgG	VNT50
S11	-	-	-	-	<20
S9	-	-	-	-	<20
S48	-	-	-	-	<20
S2	-	-	-	+	<20
S25	+	+	+	+	20
S47	+		+	+	42,9
S10	+	+	_	+	107,1
S41	+	+	+	+	139,6
S12	+		-	+	143,7
S46	+			-	148,5
S40				-	148,9
S35		-	+	+	
	+	+	+	+	153,7
S37	+	+	+	+	156,5
S8	+	+	+	+	160,4
S49	+	+	+	+	162,1
S40	+		-	+	164,4
S22	+	+	+	+	208,6
S34	+	+	+	+	218,7
S6	-	-	-	-	219,4
S44	+		+	+	225,2
S1	+	+	-	+	231,8
S26	+	+	+	+	238,2
S21	+	+	+	+	246,9
S32	+	+	+	+	251,2
S29	+	+	+	+	265,8
S45	+	+	+	+	278,1
S24	+	+	+	+	315,5
S30	+	+	+	+	345,3
S38	+		+	+	360,9
S39	+	+	+	+	361,5
S3	+	+	+	+	466
S33	+	+	+	+	489,7
S20	+	+	+	+	490,9
S43	+	+	+	+	521,6
S14	+	+	+	+	542,9
S28	+	+	+	+	579
S42	+	+	+	+	597,7
S27	+	+	+	+	605,7
S17	+	+	+	+	612,7
S36	+	+	+	+	616,1
S18	+	+	+	+	663,6
S5	+	+	+	+	663,6
 S4	+	+	+	+	846,7
S34	+	+	+	+	1025
S15	+	+	+	+	1157,1
S15 S19	+	+	+	+	
	+	+	+	+	1373,4
S23					1447,8
S13	+	+	+	+	2119,5
S16	+	+	+	+	2560
HP T1	na	-	+	-	2560
	n.a.	+		+	2560
HP_T2	n.a.	+	+	+	1454,8
HD1	n.a.	-	-	-	<20
HD2	n.a.	-	-	-	<20
HD3	n.a.	-	-		<20
HD4	n.a.	-	-	-	<20

Table 1: Serological parameters of sera and VNT_{50} values

Sera of the 49 patients are ordered by their VNT₅₀ and colour-coded. For the serological tests indicated there is a qualitative indicator for a value above the threshold (+), below the threshold (-) or borderline (0) for the respective assay. At the bottom of the table the control sera are shown. Two consecutive sera of a hospitalized patient (HP_T1/T2) and four sera of healthy donors (HD1-4). All the individual values and the specific patient characteristics are listed in Supplementary Table 1.

426 Methods

427 Study participants and sample processing. Blood was drawn from potential blood 428 donors for reconvalescent plasma therapy after written consent at the Clinical 429 Transfusion Medicine, Tübingen between April 04 and May 12, 2020, under the 430 guidelines of the local ethics committees 222/2020BO. All patients (n=49) were older 431 than 18 years old and provided a PCR-confirmed diagnosis of SCov2 (n=46) and three 432 were symptomatic and close contacts to positively diagnosed COVID-19 patients 433 (partners tested positive). All patients were non-hospitalized with asymptomatic to mild 434 courses of disease and they were fully convalescent showing no symptoms on the day 435 of blood donation. Basic demographic information was collected including age and sex. 436 as well as self-perceived symptoms (cough, fever, limb pain and headache, diarrhea, 437 and loss of taste). In addition, blood from four healthy donors and one hospitalized 438 patient was collected (Supplementary Table 1). Serum samples were stored at -80°C. 439 Cell culture. Caco-2 (Human Colorectal adenocarcinoma) cells were cultured at 37 °C

with 5% CO2 in DMEM containing 10% FCS, with 2 mM I-glutamine, 100 µg/ml penicillinstreptomycin and 1% NEAA.

442 Viruses. A throat swab sample collected in March 2020 at the diagnostic department of the Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital 443 444 Tübingen, from a SCoV2 positive patient was used to isolate the virus (200325 Tü1). 50 445 ul of patient material was diluted in media, sterile-filtrated, and used directly to inoculate 446 200.000 Caco-2 cells in a 6-well. 48 hpi (hours post-infection) the supernatant was 447 collected, centrifuged, and stored at -80°C. Supernatant as well as cell lysates from 448 infected cells were tested by Western blot using a SCoV2 anti-nucleocapsid protein (NP) 449 specific antibody (GeneTex). In addition, the identity of the virus was confirmed by qRT-

450 PCR diagnostics via S and E gene amplification. An aliquot of the isolate was used to 451 amplify the virus in a medium flask of Caco-2 cells (2X10⁶ cells) in 13 ml DMEM + 452 supplements and 5% FCS. 48 hpi, the supernatant was centrifuged and stored in 453 aliquots at -80°C.

The recombinant SCoV2 expressing mNeonGreen (icSARS-CoV-2-mNG) (17) was obtained from the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at the UTMB (University of Texas Medical Branch). To generate icSARS-CoV-2-mNG stocks, Caco-2 cells were infected as above, the supernatant was harvested 48 hpi, centrifuged, and stored at -80°C.

For MOI determination, a titration using serial dilutions of both virus stocks (200325_Tü1 and mNG) was conducted. The number of infectious virus particles per ml was calculated as the (MOI × cell number)/(infection volume), where MOI = $-\ln(1 - \ln(1 -$

464 Enzyme-linked Immunosorbent Assays (ELISAs); Euroimmun, the Euroimmun 465 SARS-CoV-2-ELISA (IgG) (Euroimmun, Lübeck, Germany) with the recombinant S1 466 target antigen of SARS-CoV-2 was performed according to manufacturer's instructions in 467 serum. Patient samples are diluted 1:101 in sample buffer. The included controls and 468 calibrator in the test kit were used with each run. Results are given as ratios (optical 469 density (OD) of control or clinical sample/OD of calibrator). According to the manufacture, ratios were classified as negative (< 0.8), borderline (\geq 0.8 - < 1.1) and 470 471 positive (≥ 1.1). Mediagnost, IgG antibody detection directed to the S1 RBD SCoV2 in 472 human sera using Mediagnost test system was made according to the manufacturer's 473 instructions. Briefly, these tests are two-step enzyme-linked immunosorbent assays. The

474 solid phase consists of a 96-well Microtiter plate (Greiner, Bio-One, Frickenhausen 475 Germany) that is coated with the recombinant SCoV2 spike protein S1. The antibodies 476 from patients that are directed against SCoV2 S1 protein bind to the solid phase coated 477 S1 protein. Next a horseradish peroxidase (HRP) conjugated goat anti-human IgG binds 478 to the human IgG antibodies. The following step involves the substrate for the HRP being 479 added by which the substrate is converted from colorless into blue color; and after 480 addition of a stop solution the color changes to yellow. The extinction of the yellow 481 solution can be measured at a wavelength at 450 nm with reference at 620 nm. 482 Increasing extinctions represent increasing amounts of antibodies to SCoV2 S1 protein. 483 Samples showing extinctions that were three times higher than the negative control can 484 be interpreted as being positive for anti- SCoV2 S1. IqA and IqM antibody detection 485 directed to the SCoV2 S1 protein was made in analogy to the above-described IgG 486 detection system except that the HRP labeled detection antibody was directed against 487 human IgA or human IgM antibodies. According to the manufacture, ratios were 488 classified as negative (<0,42), borderline ($\geq 0,42-0,7$) and positive ($\geq 0,7$) for IgG, (<0,33), 489 $(\geq 0, 33-0, 7)$ and $(\geq 0, 7)$ for IqA and (< 0, 87), $(\geq 0, 87-1, 47)$ and $(\geq 1, 47)$ for IqM.

490 Elecsys anti-SARS-CoV-2 (Roche). For qualitative detection of anti SCoV2 (IgG+IgM) 491 antibodies the electrochemiluminescence immunoassay (ECLIA) was performed using 492 the fully automated cobas e 6000/601 immunoassay analyzer (Roche Diagnostics, Mannheim, Germany). This assay targets recombinant SCoV2 nucleocapsid (NC) 493 494 protein. Two calibrators are used (Cal1 nonreactive, COI 0,101; and Cal2 reactive, COI 495 1,2) in the double antigen-sandwich based assay (SARS-CoV -2 recNC biotin label, and 496 SCoV2 recNC ruthenium complex label). Each, 20µl of sera and reference solutions 497 were used, immune complexes are fixed to streptavidin-coated microparticles. Read out

498 is given in relative light units in the form of cutoff index (COI, signal/cutoff). The Elecsys 499 reagents derived from LOT 49500101. For negative control (<150% Cal1), we used 500 pooled sera from 100 mothers at birth of the Tuebingen congenital CMV study 2012. 501 Furthermore, we used a negative control serum from a direct Covid-19 contact person, 502 repeatedly negative tested for SCoV2 RNA and nucleocapsid-specific antibodies without 503 any symptoms during and after a one week close exposition. For positive control, we 504 used a dilution series of a serum from a reconvalescent student infected symptomatically 505 (fever, cough, loss of smell) tested posiive for viral RNA and NC-specific antibodies. The 506 COIs ranged from 100 to 1. If the numeric COI result was \geq 1.0, the serum was 507 diagnosed as reactive, COI <1.0 were attributed as non-reactive. COI values of the 508 positive controls were stable over at least 2 months.

509 Multiplexed detection of anti-coronavirus antibodies. Whole viral protein lysates from 510 229E, OC43, and NL63 (ZeptoMetrix Corp) and from SCoV2 were used for DigiWest as 511 described (13). Viral protein lysates were used for denaturing gel electrophoresis and 512 Western blotting using the NuPAGE system. Blot membranes were washed with PBST 513 (0.1% Tween-20, PBS) and membrane-bound proteins were biotinylated by adding 50 514 µM NHS-PEG12-Biotin (Thermo Fisher Scientific) in PBST for 1 h. After washing in 515 PBST, membranes were dried overnight. Subsequently, the Western-Blot lanes were cut 516 into 96 strips of 0.5 mm width and were transferred to a 96-well plate (Greiner Bio-One). 517 For protein elution, 10 µL of elution buffer was added to each well (8 M urea, 1% Triton-518 X100 in 100 mM Tris-HCl pH 9.5). The protein eluates were diluted with 90 µL dilution 519 buffer (5% BSA in PBST, 0.02% sodium azide). Neutravidin-coated MagPlex beads 520 (Luminex) of a distinct colour ID were added to the protein eluates and binding was 521 allowed overnight; 500 µM PEG12-biotin in PBST was added to block remaining

522 Neutravidin binding sites. The bead containing fractions were pooled and thereby the 523 original Western blot lanes were reconstituted. Beads were washed in PBST and 524 resuspended in store buffer (1% BSA, 0.05 % azide, PBS). The generated bead-set 525 represents the proteomes of the four coronaviruses (SCoV2, OC43, 229E, NL63) and 526 reactivity against all proteins can be tested in one assay.

527 For serum incubation, 5 µL of the bead mix were equilibrated in 50 µL serum assay 528 buffer (Blocking Reagent for ELISA (Roche) supplemented with 0.2% milk powder, 529 0.05% Tween-20 and 0.02% sodium azide, 25% Low Cross buffer (Candor Bioscience), 530 25% IgM-reducing agent buffer (ImmunoChemistry). Serum assay buffer was discarded 531 and 30 µL of diluted patient serum (1:200 in serum assay buffer) was added and 532 incubated for 2 hours at RT on a shaker. After washing in PBST, 30 µL of Phycoerythrin 533 labelled anti-human IgG secondary antibody (diluted 1:200 in serum assay buffer; Dianova) was added and incubated for 45 min at 23 °C. The beads were washed twice 534 535 with PBST and readout was performed on a Luminex FlexMAP 3D.

536 The DigiWest analysis tool was used to assess serum reactivity against the viral proteins 537 (13). Virus protein-specific peaks were identified and average fluorescence intensity 538 (AFI) values were calculated by integration of peak areas.

Neutralization assay. For neutralization experiments, $1 \square \times 10^4$ Caco-2 cells/well were seeded in 96-well plates the day before infection in media containing 5% FCS. Cells were co-incubated with SARS-CoV-2 clinical isolate 200325_Tü1 at a MOI=0.3 and patient sera in serial two-fold dilutions from 1:20 up to 1:2560. 48 hpi cells were fixed with 80% acetone for 5 minutes, washed with PBS, and blocked for 30 minutes at room temperature (rt) with 10 % normal goat serum (NGS). Cells were incubated for 1 h at rt with 100 µl of serum from a hospitalized convalescent donor in a 1:1000 dilution and

546 washed 3 times with PBS. 100 µl of goat anti-human Alexa594 1:2000 in PBS was used 547 as secondary antibody for 1h at rt. Cells were washed 3 times with PBS and counter-548 stained with 1:20000 DAPI solution (2 mg/ml) for 10 minutes at rt. For quantification of 549 infection rates images were taken with the Cytation3 (Biotek) and DAPI+ and Alexa594+ 550 cells were automatically counted by the Gen5 Software (Biotek).

551 Alternatively, Caco-2 cells were co-incubated with the SARS-CoV-2 strain icSARS-CoV-552 2-mNG at a MOI=1.1 and patient sera in serial two-fold dilutions from 1:40 up to 1:5120. 553 48 hpi cells were fixed with 2% PFA and stained with Hoechst33342 (1 µg/mL final 554 concentration) for 10 minutes at 37°C. The staining solution was removed and 555 exchanged for PBS. For quantification of infection rates images were taken with the 556 Cytation3 (Biotek) and Hoechst+ and mNG+ cells were automatically counted by the 557 Gen5 Software (Biotek). Virus neutralizing titers (VNT_{50}) were calculated as the half-558 maximal inhibitory dose (ID50) using 4-parameter nonlinear regression (GraphPad 559 Prism).

560 **Software and statistical analysis.** GraphPad Prism 8.0 was used for statistical and 561 correlation analyses and to generate graphs. Figures were generated with CorelDrawX7. 562 Other software used included Gen5 v.3.04.

563